Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
McKesson
Cipla
Cerilliant
UBS
Teva
Daiichi Sankyo
Healthtrust
US Army

Generated: May 23, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 090825

« Back to Dashboard

NDA 090825 describes IMIPENEM AND CILASTATIN, which is a drug marketed by Acs Dobfar and Hospira Inc and is included in three NDAs. It is available from three suppliers. Additional details are available on the IMIPENEM AND CILASTATIN profile page.

The generic ingredient in IMIPENEM AND CILASTATIN is cilastatin sodium; imipenem. There are sixteen drug master file entries for this compound. Four suppliers are listed for this compound. Additional details are available on the cilastatin sodium; imipenem profile page.
Summary for 090825
Tradename:IMIPENEM AND CILASTATIN
Applicant:Hospira Inc
Ingredient:cilastatin sodium; imipenem
Patents:0
Therapeutic Class:Antibacterials
Formulation / Manufacturing:see details
Pharmacology for NDA: 090825
Ingredient-typeCarbapenems
Mechanism of ActionDipeptidase Inhibitors
Suppliers and Packaging for NDA: 090825
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
IMIPENEM AND CILASTATIN cilastatin sodium; imipenem POWDER;INTRAVENOUS 090825 ANDA Hospira, Inc. 0409-3507 N 0409-3507-01
IMIPENEM AND CILASTATIN cilastatin sodium; imipenem POWDER;INTRAVENOUS 090825 ANDA Hospira, Inc. 0409-3508 N 0409-3508-01

Profile for product number 001

Active Rx/OTC/Discontinued:DISCNDosage:POWDER;INTRAVENOUSStrengthEQ 250MG BASE/VIAL;250MG/VIAL
Approval Date:Nov 16, 2011TE:RLD:No

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:POWDER;INTRAVENOUSStrengthEQ 500MG BASE/VIAL;500MG/VIAL
Approval Date:Nov 16, 2011TE:APRLD:No

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Farmers Insurance
Colorcon
Daiichi Sankyo
McKinsey
US Department of Justice
Cipla
Merck
Teva
Cerilliant

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.